Free Trial

iRadimed (IRMD) Stock Price, News & Analysis

iRadimed logo
$93.60 0.00 (0.00%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$93.56 -0.04 (-0.05%)
As of 06/12/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About iRadimed Stock (NASDAQ:IRMD)

Advanced

Key Stats

Today's Range
$92.94
$97.36
50-Day Range
$83.44
$97.33
52-Week Range
$55.11
$107.90
Volume
175,213 shs
Average Volume
148,581 shs
Market Capitalization
$1.20 billion
P/E Ratio
51.15
Dividend Yield
0.85%
Price Target
$120.00
Consensus Rating
Buy

Company Overview

iRadimed Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

IRMD MarketRank™: 

iRadimed scored higher than 68% of companies evaluated by MarketBeat, and ranked 280th out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    iRadimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    iRadimed has a consensus price target of $120.00, representing about 28.2% upside from its current price of $93.60.

  • Amount of Analyst Coverage

    iRadimed has only been the subject of 2 research reports in the past 90 days.

  • Read more about iRadimed's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of iRadimed is 51.15, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.99.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of iRadimed is 51.15, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.99.

  • Price to Book Value per Share Ratio

    iRadimed has a P/B Ratio of 12.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about iRadimed's valuation and earnings.
  • Percentage of Shares Shorted

    8.08% of the float of iRadimed has been sold short.
  • Short Interest Ratio / Days to Cover

    iRadimed has a short interest ratio ("days to cover") of 4.18.
  • Change versus previous month

    Short interest in iRadimed has recently decreased by 1.23%, indicating that investor sentiment is improving.
  • Dividend Yield

    iRadimed has a dividend yield of 0.85%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    iRadimed has only been increasing its dividend for 1 years.

  • Dividend Coverage

    The dividend payout ratio of iRadimed is 43.72%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about iRadimed's dividend.
  • News Sentiment

    iRadimed has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for iRadimed this week, compared to 3 articles on an average week.
  • Search Interest

    6 people have searched for IRMD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, iRadimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,794,878.00 in company stock.

  • Percentage Held by Insiders

    34.60% of the stock of iRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    92.34% of the stock of iRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about iRadimed's insider trading history.
Receive IRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iRadimed and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IRMD Stock News Headlines

iRadimed (NASDAQ:IRMD) CEO Sells $226,500.00 in Stock
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel
IRadimed Rides 3870 Momentum Despite Near-Term Dip
Iradimed Corp Eyes 2026 Surge After Strong Quarter
See More Headlines

IRMD Stock Analysis - Frequently Asked Questions

iRadimed's stock was trading at $97.28 at the beginning of 2026. Since then, IRMD shares have decreased by 3.8% and is now trading at $93.60.

iRadimed Corporation (NASDAQ:IRMD) announced its earnings results on Friday, May, 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.03. The medical equipment provider earned $21.98 million during the quarter, compared to the consensus estimate of $21.32 million. iRadimed had a net margin of 27.36% and a trailing twelve-month return on equity of 24.48%.
Read the conference call transcript
.

iRadimed (IRMD) raised $13 million in an initial public offering on Wednesday, July 16th 2014. The company issued 2,016,000 shares at a price of $6.25 per share.

iRadimed's top institutional investors include Renaissance Technologies LLC (3.45%), Copeland Capital Management LLC (2.81%), Dimensional Fund Advisors LP (1.77%) and Ranger Investment Management L.P. (0.87%). Insiders that own company stock include Roger E Susi, James B Hawkins, Monty K Allen, Anthony Vuoto and John Glenn.
View institutional ownership trends
.

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that iRadimed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/01/2026
Record date for 5/29 Dividend
5/15/2026
Ex-Dividend for 5/29 Dividend
5/15/2026
Dividend Payable
5/29/2026
Today
6/15/2026
Next Earnings (Estimated)
7/30/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:IRMD
CIK
1325618
Employees
110
Year Founded
2004

Price Target and Rating

High Price Target
$120.00
Low Price Target
$120.00
Potential Upside/Downside
+28.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.83
Trailing P/E Ratio
51.15
Forward P/E Ratio
61.58
P/E Growth
N/A
Net Income
$22.48 million
Net Margins
27.36%
Pretax Margin
34.98%
Return on Equity
24.48%
Return on Assets
21.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.13
Quick Ratio
6.15

Sales & Book Value

Annual Sales
$83.81 million
Price / Sales
14.27
Cash Flow
$1.86 per share
Price / Cash Flow
50.35
Book Value
$7.44 per share
Price / Book
12.58

Miscellaneous

Outstanding Shares
12,780,000
Free Float
8,360,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
0.91

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:IRMD) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners